{"id":8158,"date":"2023-04-06T18:46:17","date_gmt":"2023-04-06T18:46:17","guid":{"rendered":"https:\/\/www.yuhan-usa.com\/?p=8158"},"modified":"2023-09-06T17:48:45","modified_gmt":"2023-09-06T17:48:45","slug":"yuhan-corporation-acquires-progen-a-multi-target-antibody-company-based-in-south-korea-for-total-of-23m-investment","status":"publish","type":"post","link":"https:\/\/www.yuhan-usa.com\/yuhan-corporation-acquires-progen-a-multi-target-antibody-company-based-in-south-korea-for-total-of-23m-investment\/","title":{"rendered":"Yuhan Corporation acquires Progen, a multi-target antibody company based in South Korea for total of $23M investment"},"content":{"rendered":"\n<p>Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target antibody-based platform technology.&nbsp;<\/p>\n\n\n\n<p>Progen Inc. is a biotechnology company with 25 years of experience in platform-based drug discovery and development. The company has a platform technology for immunoglobulin fusion protein NTIG (Neo Tri-ImmunoGlobulin) with multi-target targeting and long-term persistence.&nbsp;<\/p>\n\n\n\n<p>Yuhan will invest a total of $23million through the acquisition of Progen&#8217;s old and new shares, thereby securing a 38.9% stake in Progen and becoming the sole largest shareholder. The company plans to complete the acquisition process before early May.&nbsp;<\/p>\n\n\n\n<p>Through this acquisition, Yuhan will increase its ability to develop new drugs such as multi-target antibody therapeutics and strengthen domestic and international partnerships by establishing an Open Innovation Center with Progen.&nbsp;<\/p>\n\n\n\n<p>Previously, Yuhan and Progen signed a research collaboration MOU for the development of bio-innovative new drugs in September last year.&nbsp;<\/p>\n\n\n\n<p>Original article (Korean): https:\/\/www.yna.co.kr\/view\/AKR20230405099100017?input=1195m<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target antibody-based platform technology.&nbsp; Progen Inc. is a biotechnology company with 25 years of experience in platform-based drug discovery and development. The company has a platform technology for immunoglobulin [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[56],"tags":[57,52],"_links":{"self":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/8158"}],"collection":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/comments?post=8158"}],"version-history":[{"count":2,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/8158\/revisions"}],"predecessor-version":[{"id":9538,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/posts\/8158\/revisions\/9538"}],"wp:attachment":[{"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/media?parent=8158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/categories?post=8158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.yuhan-usa.com\/wp-json\/wp\/v2\/tags?post=8158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}